This is a non-core endpoint: only basic statistics are computed.
Chondrosarcoma
C3_CHONDROSARCOMA
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
116 |
4. Check minimum number of eventsNone |
116 |
5. Include endpointsNone |
116 |
6. Filter based on genotype QC (FinnGen only) |
111 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Chondrosarcoma
based on the number of shared cases.
Similar with more cases:
- Chondrosarcoma, including Hilmo
- Solid cancers
- Malignant neoplasm
- Malignant neoplasm
- Solid cancers, including Hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 111 | 50 | 61 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 56.23 | 54.63 | 57.55 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 113
- Matched controls
- 1130
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
130.2
35.1
36
*
C40.22
ICD-10 Finland
Chondrosarcoma of the long bones of the lower extremity
+∞
30.6
28
*
9220/3-C40.2
ICD-O-3
Chondrosarcoma, NOS, of long bones of lower limb and associated joints
+∞
28.3
26
*
130
Kela drug reimbursment
Malignant tumour
+∞
22.7
21
*
WX408
NOMESCO Finland
General anesthesy, balanced
6.4
21.6
56
151
C40.20
ICD-10 Finland
Malignant tumor of the long bones of the lower extremity without histology
+∞
18.2
17
*
C41.32
ICD-10 Finland
Chondrosarcoma of the ribs, sternum and clavicle
+∞
18.2
17
*
9220/3-C41.3
ICD-O-3
Chondrosarcoma, NOS, of rib, sternum, clavicle and associated joints
+∞
17.1
16
*
C40.02
ICD-10 Finland
Chondrosarcoma of the scapula and long bones of the upper extremity
+∞
14.9
14
*
GAE06
NOMESCO Finland
Excision of lesion of chest wall
+∞
13.8
13
*
H02AB02
ATC
dexamethasone; systemic
57.1
13.2
15
*
C41.82
ICD-10 Finland
Overall chondrosarcoma in bone and articular cartilage
+∞
12.7
12
*
XX3DW
NOMESCO Finland
Time consuming IT work
13.4
12.7
22
20
D16.2
ICD-10 Finland
Benign neoplasm: Long bones of lower limb
72.7
11.9
13
*
NFR30
NOMESCO Finland
Extended excision of soft tissue tumour of hip or thigh
+∞
11.7
11
*
9220/3-C41.4
ICD-O-3
Chondrosarcoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
11.7
11
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
9.8
11.0
22
27
9220/3-C40.0
ICD-O-3
Chondrosarcoma, NOS, of long bones of upper limb, scapula and associated joints
+∞
10.6
10
*
C41.42
ICD-10 Finland
Chondrosarcoma of the pelvic bones, sacrum and coccyx
+∞
10.6
10
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
11.8
10.5
19
19
WX402
NOMESCO Finland
General anaesthesia
4.1
10.5
38
125
ZXE30
NOMESCO Finland
More than five and less than seven hours
19.0
10.2
15
9
B01AB05
ATC
enoxaparin; parenteral
3.6
9.9
51
212
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
60.3
9.8
11
*
B01AB10
ATC
tinzaparin; parenteral
5.7
9.7
20
41
L03AA13
ATC
pegfilgrastim; parenteral
108.8
9.6
10
*
NK6BN
NOMESCO Finland
Bone dynamic isotope examination
+∞
9.5
9
*
C32.3
ICD-10 Finland
Malignant neoplasm: Laryngeal cartilage
+∞
9.5
9
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
9.5
9
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
15.5
9.5
15
11
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
26.6
9.1
12
5
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
9.0
71
378
R4110
NOMESCO Finland
Physiotherapy
3.3
8.6
47
199
WF002
NOMESCO Finland
Radical radiotherapy
97.0
8.5
9
*
JN4BD
NOMESCO Finland
Extensive body CT
7.9
8.5
19
28
ZXE20
NOMESCO Finland
More than three and less than five hours
4.1
8.4
27
80
C41.06
ICD-10 Finland
Chondrosarcoma of the skull or facial bones except maxilla
+∞
8.4
8
*
C41.3
ICD-10 Finland
Malignant neoplasm: Ribs, sternum and clavicle
+∞
8.4
8
*
GAE23
NOMESCO Finland
Resection of chest wall and prosthetic repair
+∞
8.4
8
*
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
+∞
8.4
8
*
9220/3-C41.0
ICD-O-3
Chondrosarcoma, NOS, of bones of skull and face and associated joints
+∞
8.4
8
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.1
8.1
51
234
JN4AD
NOMESCO Finland
Body CT examination
7.2
7.6
18
29
A03FA01
ATC
metoclopramide; systemic, rectal
3.9
7.5
26
81
ZXB10
NOMESCO Finland
Medial
85.5
7.5
8
*
A04AA02
ATC
granisetron; systemic, transdermal
85.5
7.5
8
*
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
85.5
7.5
8
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
17.2
7.4
11
7
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
7.4
7
*
C41.22
ICD-10 Finland
Chondrosarcoma of the spine
+∞
7.4
7
*
9220/3-C32.3
ICD-O-3
Chondrosarcoma, NOS, of laryngeal cartilage
+∞
7.4
7
*
NER30
NOMESCO Finland
Extended excision of soft tissue tumour of pelvis
+∞
7.4
7
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.4
7
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
7.4
7
*
C40.2
ICD-10 Finland
Malignant neoplasm: Long bones of lower limb
+∞
7.4
7
*
DQB20
NOMESCO Finland
Partial excision of larynx
+∞
7.4
7
*
115
Kela drug reimbursment
Breast cancer
+∞
7.4
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.4
7
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
7.4
7
*
TPH07
NOMESCO Finland
Cathetrisation of artery
4.0
7.3
24
72
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.5
7.3
31
111
GBB00
NOMESCO Finland
Tracheostomy
21.7
7.3
10
5
ZXE40
NOMESCO Finland
More than seven and less than nine hours
42.7
6.8
8
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.8
6.7
54
278
QA1S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in head
73.8
6.5
7
*
NGR20
NOMESCO Finland
Intralesional or marginal excision of tumor of knee or lower leg
73.8
6.5
7
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
73.8
6.5
7
*
NFB60
NOMESCO Finland
Demanding prosthetic replacement of hip
73.8
6.5
7
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
73.8
6.5
7
*
NF3AA
NOMESCO Finland
Femur X-ray examination
8.5
6.3
13
17
NBR20
NOMESCO Finland
Intralesional or marginal excision of soft tissue tumour of shoulder or upper arm
+∞
6.3
6
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
6.3
6
*
DQD50
NOMESCO Finland
Endoscopic insertion of stent in larynx
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
C40.00
ICD-10 Finland
Malignant tumor of the scapula and the long bones of the upper extremity without histology
+∞
6.3
6
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
17071
ICD-8 Finland
Malignant neoplasm of bone, Lower limb, long bones
+∞
6.3
6
*
WZC30
NOMESCO Finland
Teaching
3.4
6.2
25
86
NG4AA
NOMESCO Finland
Lower leg X-ray examination
10.9
6.2
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
77
395
3.98
11.07
3.9
2.5
—
—
estimate
—
0
0
52
216
3.61
10.13
3.8
2.1
—
—
—
0
0
20
47
4.96
8.33
2.3
2.0
1.83
2.95
ug/l
1.90
15
35
30
112
3.29
6.57
8.8
9.0
0.34
1.32
mmol/l
0.97
25
93
75
512
2.38
4.53
9.0
6.6
4.87
4.28
e9/l
0.27
67
436
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
26
5.03
4.20
2.0
2.5
0.30
0.38
iu/ml
—
6
13
19
76
2.80
3.60
2.7
3.2
—
—
—
0
0
9
18
5.33
3.45
1.4
1.4
—
—
—
0
0
62
421
2.05
3.43
7.3
6.4
1.20
1.21
mmol/l
0.64
55
386
7
12
6.14
3.07
1.0
1.2
—
—
—
0
0
7
12
6.14
3.07
1.0
1.2
—
—
—
0
0
59
411
1.91
2.88
4.3
3.9
34.94
35.94
g/l
0.67
54
392
65
474
1.87
2.69
7.1
7.1
1.21
1.21
mmol/l
0.05
55
424
14
62
2.44
2.18
2.9
1.9
69.00
62.17
ml/min/173m2
—
7
18
74
588
1.75
2.07
6.6
4.8
6.42
6.72
mmol/l
0.77
68
557
18
93
2.11
1.98
4.7
2.1
265.17
235.85
u/l
0.37
18
88
20
108
2.04
1.97
1.3
1.8
—
—
—
0
0
21
119
1.94
1.82
1.5
1.7
—
—
—
0
0
0
47
0.00
1.75
0.0
1.0
—
—
—
0
0
5
13
3.97
1.73
2.8
3.2
12.14
12.78
mg/l
—
5
13
6
21
2.96
1.52
1.3
2.8
4.40
3.96
g/l
—
6
21
24
153
1.72
1.44
1.7
1.8
—
—
—
0
0
13
68
2.03
1.40
1.7
2.4
0.19
0.21
g/l
0.75
13
61
23
147
1.71
1.37
2.0
2.5
0.82
0.83
mmol/l
0.26
23
141
101
918
1.94
1.36
20.6
14.2
31.97
23.73
mg/l
1.63
89
736
96
860
1.77
1.35
4.9
5.1
2.03
1.92
mu/l
0.36
84
786
5
18
2.86
1.30
1.4
2.0
—
—
—
0
0
20
126
1.71
1.25
2.4
6.6
0.98
1.07
mmol/l
0.85
20
117
18
110
1.76
1.24
1.6
2.3
4.33
5.70
umol/l
1.28
18
99
5
20
2.57
1.16
1.8
1.1
—
—
—
0
0
21
139
1.63
1.10
9.6
7.3
103.76
104.24
mmol/l
0.16
21
139
10
52
2.01
1.10
2.6
4.2
2.00
2.14
mmol/l
—
10
32
97
886
1.67
1.08
20.2
13.6
83.76
77.84
ml/min/173m2
1.75
86
816
6
28
2.21
0.93
1.7
1.2
—
—
—
0
0
6
29
2.13
0.91
2.0
3.9
—
—
—
0
0
106
1008
1.83
0.84
32.4
21.6
90.77
91.32
fl
0.49
106
997
106
1009
1.82
0.84
33.8
22.2
39.25
40.79
%
2.87
106
998
16
227
0.66
0.78
1.1
1.3
1.48
1.20
u/ml
—
5
64
104
988
1.66
0.76
13.8
10.3
25.49
25.59
u/l
0.02
99
957
5
24
2.13
0.75
1.2
2.7
91.40
91.00
%
—
5
24
5
24
2.13
0.75
1.6
1.4
—
—
—
0
0
32
252
1.38
0.74
2.6
2.9
0.34
0.35
e6/l
0.02
24
173
18
127
1.50
0.73
4.8
5.2
33.00
32.67
%
0.06
11
80
5
25
2.04
0.73
1.8
1.2
353.80
3.35
e6/l
—
5
20
5
25
2.04
0.73
1.8
1.4
351.80
425.05
e6/l
—
5
20
9
57
1.63
0.73
1.4
1.5
—
—
—
0
0
106
1010
1.80
0.72
32.8
21.7
130.07
136.65
g/l
4.03
106
998
79
716
1.34
0.70
4.5
4.5
15.91
11.55
mm/h
1.04
74
660
0
20
0.00
0.61
0.0
1.1
—
0.18
—
0
5
34
279
1.31
0.60
5.7
3.8
0.00
0.00
estimate
-0.00
12
87
8
53
1.55
0.60
1.5
1.3
—
—
—
0
0
18
133
1.42
0.59
1.4
1.4
—
—
—
0
0
57
504
1.26
0.56
4.8
4.0
0.00
0.00
estimate
-0.00
12
97
85
904
0.76
0.55
6.4
6.9
38.20
40.03
mmol/mol
1.02
73
847
6
96
0.60
0.55
2.2
2.6
0.10
0.31
e6/l
—
6
90
39
330
1.28
0.55
2.9
3.2
—
—
—
0
0
57
510
1.24
0.49
4.7
4.0
0.00
0.00
estimate
-0.00
11
87
88
927
0.77
0.47
4.7
5.6
4.33
4.50
mmol/l
0.82
76
870
88
925
0.78
0.44
4.7
5.4
1.48
1.46
mmol/l
0.13
76
862
5
33
1.54
0.42
1.4
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
90
941
0.79
0.40
5.3
6.3
2.40
2.60
mmol/l
1.42
79
879
0
18
0.00
0.40
0.0
1.0
—
1.61
—
0
11
55
498
1.20
0.40
4.7
3.9
0.00
0.00
estimate
-0.00
11
90
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
5
36
1.41
0.38
1.4
1.6
—
—
—
0
0
10
72
1.43
0.38
1.0
1.4
—
—
—
0
0
59
640
0.84
0.38
2.7
3.2
41.62
44.70
u/l
0.23
53
604
43
387
1.18
0.32
5.2
3.8
0.00
0.01
estimate
0.49
11
74
20
167
1.24
0.31
2.6
2.9
0.54
1.13
e6/l
—
9
87
38
421
0.85
0.29
1.7
2.0
1.14
1.32
mmol/l
1.18
31
369
74
700
1.17
0.28
4.5
4.0
14.49
14.96
pmol/l
0.75
65
642
52
480
1.15
0.27
2.0
2.1
86.77
95.31
pmol/l
0.61
27
240
48
441
1.15
0.27
2.0
2.6
84.16
76.13
nmol/l
1.31
43
386
9
74
1.23
0.26
1.7
1.8
—
—
—
0
0
5
37
1.37
0.24
2.0
1.3
0.00
0.00
g/l
—
5
32
27
240
1.16
0.23
4.7
4.4
1.02
1.02
kg/l
0.97
20
159
5
41
1.23
0.22
1.6
2.0
35.00
46.40
u/l
—
5
35
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
935.36
—
0
11
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
310.95
—
0
12
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
34
310
1.14
0.21
2.9
2.7
33.21
37.82
u/l
0.24
34
295
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
86
883
0.89
0.15
3.9
4.6
1.15
1.26
mmol/l
1.34
75
820
10
84
1.21
0.14
1.7
4.6
342.60
231.83
ng/l
—
10
75
35
327
1.10
0.14
2.7
3.2
1832.28
1406.62
ng/l
0.15
29
271
34
361
0.92
0.12
3.1
4.2
3.19
9.67
mg/mmol
1.93
16
231
90
918
0.90
0.11
4.6
5.3
5.75
6.01
mmol/l
2.00
74
835
14
125
1.14
0.10
5.9
6.5
—
—
—
0
0
9
87
1.04
0.07
1.8
1.7
—
—
—
0
0
29
277
1.06
0.06
4.6
3.5
0.00
0.00
estimate
-0.00
11
70
30
311
0.95
0.04
5.0
3.8
23.67
24.77
%
0.14
17
137
10
109
0.91
0.04
1.5
1.5
—
—
—
0
0
16
158
1.01
0.00
2.5
3.2
4.80
2.61
e6/l
—
5
79
40
405
0.98
0.00
4.3
4.0
31.23
41.74
ng/l
0.42
30
291
18
181
0.99
0.00
1.5
1.7
1438.27
1173.60
nmol/l
0.40
11
136
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
38.60
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
30.76
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
851.83
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
9
97
0.92
-0.00
2.7
1.7
319.67
389.10
nmol/l
—
9
88
5
59
0.84
-0.00
2.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
54
540
1.00
-0.00
3.7
2.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_CHONDROSARCOMA – Chondrosarcoma
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).